Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interi... (ation pathway for OPAXIO. We...)

HOME >> MEDICINE >> TECHNOLOGY

Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis

Date:9/21/2009

ation pathway for OPAXIO."

"We believe focusing on ovarian maintenance, and radiosensitization, not only address areas of unmet medical need, but are in the best long term strategic interest of CTI. With the FDA review of the NDA for pixantrone in relapsed/refractory non-Hodgkin's lymphoma well underway and the phase III Ovarian trial of OPAXIO progressing nicely we are pleased with the advancement and future potential of these novel treatments," said James A. Bianco, M.D., CEO of CTI.

CTI has an existing license and co-development agreement with Novartis for OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About OPAXIO

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncol
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial

Post Your Comments:

(Date:12/15/2009)... PARK, Calif., Dec. 15 SRI International, ... today the award of U.S. patent 7,592,021 for ... enhanced release of drugs through the human body,s ... drug delivery and allows for a much longer ... or liquids. ,, Transmucosal delivery is an effective ...

(Date:12/15/2009)... medical expert internationally recognized as a leading authority ... last month to suspend Doug Barron for doping ... the medical condition hypogonadism and was ... and discriminatory." ,, Hypogonadism is the ... referred to informally as Low T . ...

(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...

Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2 SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3 SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4 SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5 Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2 Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3 Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4 Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2 SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 1 SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 2 SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 3 Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 1 Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 2 Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 3 Over One Thousand Blind Americans to March in Detroit 50418 1 Over One Thousand Blind Americans to March in Detroit 50418 2

[0] SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System [0] Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory'[0] Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets

... Developed Through Joint Venture Between Bristol-Myers Squibb and ... of Its Kind in HIV Treatment -, PRINCETON, ... European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 ... for commercialization in the,27 countries of the European Union, ...

... into Treatment Impact, Node-Positive ... Breast Cancer, Measuring ER/PR Scores, REDWOOD CITY, Calif., Dec. ... results from multiple studies,reinforcing the clinical utility of the company,s ... recurrence and the,likelihood of chemotherapy benefit for a large portion ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)

(Date:12/15/2009)... it,s still too early to say that ... TUESDAY, Dec. 15 (HealthDay News) -- Common chemicals ... to the abnormal growth of breasts in boys, ... in a prominent medical journal for pediatricians, adds ... phthalates, whose safety has been questioned by some ...

(Date:12/15/2009)... when doctors decide benefits of imaging outweigh the risks ... can pose a serious risk to people with heart ... researchers exposed pacemakers to a simulated MRI magnetic field ... tip of the pacemaker lead, where it would touch ... to MRI magnetic pulses caused certain pacemakers to deliver ...

(Date:12/15/2009)... Accelify is proud to announce the addition ... David will serve as Director of Development in the ... Board of Advisors. ,, David Tokofsky was ... of Education in June 1995. As the Board Member ... 600,000 stretching from Northeast Los Angeles through East Los ...

(Date:12/15/2009)... and acquisitions are commonplace today. As competitors come ... a product portfolio they also must face integration ... A new free, white paper from Howard Leight ... Program: US Airways ," details how the merger ... newly formed company to enhance its occupational Hearing ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...

[0] Breast Growth in Boys Might Be Linked to Plastics Chemical [0] Patients With Pacemakers Should Avoid MRI Scans [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... A new study has found that a compound from olive-pomace ... ,Researchers from the University of Granada and Hospital Carlos ... from olive skin, inhibits serin-protease, the enzyme used by HIV ... cellular environment and, subsequently, to spread the infection into the ...

... the University of Texas M. D. Anderson Cancer Center ... therapy selectively embeds a gene in pancreatic cancer ... survival virtually without toxicity. ,"This vehicle, ... cancer-specific expression that it can be used for therapy ...

... from Cushings Syndrome can breathe a bit easily now. ... orphan drug status for its Corlux from the Food ... a disorder caused by prolonged exposure of the body's ... , ,Symptoms vary, but most people have high ...

... who smoke, may be at an increased risk of respiratory ... balanced diet . ,The finding comes from a ... Public Health, Health Canada, Brigham and Women's Hospital, and the ... School of Public Health who found that teens whose diet ...

... at The University of Nottingham have just given people another ... more muscle mass in old age than non-smokers . ... posed by smoking such as cancer, heart attacks and strokes. ... to have a lower muscle mass than non-smokers, for the ...

... Duke University has created high resolution, three-dimentional microscopic images ... of the organ. ,The researchers could ... magnetic resonance imaging. ,"These images can ... clinical MRI scan," said G. Allan Johnson, Duke's Charles ...

Other Medicine News:Health News:Gene Therapy Eradicates Pancreatic Cancer in Mice 2 Health News:FDAs Gesture for Firm Manufacturing Drug for Cushings Syndrome 2 Health News:A Balanced Diet can Keep Asthma, Wheezing at Bay in Teens 2 Health News:Smoking Speeds Up Muscle Loss 2 Health News:Now, 'virtual' Mouse Brains Available on the Net 2

Olive-pomace Oil Compound Inhibits HIV Spread Gene Therapy Eradicates Pancreatic Cancer in Mice FDAs Gesture for Firm Manufacturing Drug for Cushings Syndrome A Balanced Diet can Keep Asthma, Wheezing at Bay in Teens Smoking Speeds Up Muscle Loss Now, 'virtual' Mouse Brains Available on the Net

Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....

... BacT/Alert 3D Signature is a state ... system that integrates blood, sterile body ... a powerful microbiology workstation with comprehensive ... volume identification and where expanded flexibility ...

... automated instrument that offers Rapid results (with ... same day turnaround), random or batch processing ... used for bacterial and yeast identification, antimicrobial ... a complete data management system. It processes ...

IDS Rapid One, a microbial identification system....

Medicine Products:

Sugita Aneurysm Clip Bent BacT/Alert 3D Signature Vitek IDS Rapid One

Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interi...(ation pathway for OPAXIO. We...),Health